Summary Assessment of tumour response to chemotherapy is important when assessing efficacy of treatment and comparing differing therapeutic regimens. Percentage hepatic replacement (PHR) is commonly used to assess response to treatment of colorectal hepatic metastases. PHR is dependent not only on tumour volume, but also on hepatic parenchymal volume. The effect of tumour growth on hepatic parencymal volume is unclear but is of importance owing to its effect on PHR. We assessed tumour and hepatic parenchymal weights in an animal tumour model using dissection, and tumour and hepatic parenchymal volumes in patients with colorectal hepatic metastases using CT scanning, (Miller et al., 1981) .
More patients with colorectal liver metastases are being treated with chemotherapy following studies which suggest that chemotherapy prolongs survival (Erlichman et al., 1988; Rougier et al., 1992; Allen-Mersh et al., 1994) . As only 40-60% of colorectal liver metastasis patients respond to chemotherapy (Dworkin et al., 1991) , and the duration of response is limited, it is necessary to monitor the effect of treatment on the tumour -both after routine treatment and in trials comparing treatments. Conventional chemotherapy response criteria involve assessment of tumour shrinkage (Allen-Mersh et al., 1987) , a tumour partial response being defined as a 50% reduction in tumour size in two dimensions, measured either clinically or radiologically (Miller et al., 1981) . Although tumour response can be estimated, these methods do not provide an estimate of extent of disease, which is required in clinical trials in which treatment groups must be balanced for extent of disease.
At present, the most accurate and reproducible method of assessing colorectal liver metastasis size is by CT scanning (Ward et al., 1988; Hunt et al., 1989) . Measurement of area of metastases and liver on each CT scan slice can be translated into volume by the principle of Delesse (1847). Response can then be assessed by comparing percentage hepatic replacement (PHR) before and after treatment (Breiman et al., 1982) . PHR is the quotient of the metastasis volume divided by the total liver parenchymal and metastasis volume expressed as a percentage and provides an indication of extent of disease. As PHR is a ratio, it has the advantage of removing scale change errors arising from variation in CT scan protocols or equipment. However, PHR also depends on liver parenchymal volume, and the relationship between this and change in metastasis volume is not clear.
The aims of this study were to assess how liver parenchymal volume changes with metastasis growth or shrinkage, and thereby to determine how closely PHR reflects change in metastasis volume. In addition, we compared the accuracy of conventional WHO criteria (Miller et al., 1981) verted to square millimetres using the scale given with each CT scan. Volume for each slice was obtained by multiplying this area by the slice thickness. The total volumes (liver and metastasis) were derived by summing contiguous slices using a previously described method (Breiman et al., 1982) . Liver parenchymal volume was also similarly assessed in 13 control patients with normal livers undergoing abdominal CT for unrelated conditions.
The correlation between variables was obtained using Pearson's correlation coefficient and differences between variables were assessed using Student's t-test.
Sequential scan patient study Twenty patients who had either uncontrolled metastasis growth (n = 10) or treatment-induced metastasis shrinkage (n = 10) were scanned on two separate occasions with a 4-6 month interval between scans. Measurements were made as outlined above, and the extent of disease compared between scans from the same patient using the paired-rank test. For assessment of change in size by WHO criteria (Miller et al., 1981) , the product of the largest diameter of a metastasis and the largest perpendicular to that diameter was obtained for every metastasis above 5 cm diameter. These were saved from all scan slices, and the total before and after treatment compared to determine whether there had been progressive disease (>25% increase), stable disease (<25% increase to <50% decrease), a partial response (> 50% decrease) or a complete response (disappearance of visible tumour).
Results

Animal study
The median weight of animals studied was 320 g (range 290-360 g). There was no significant correlation between liver parenchymal weight and metastasis weight (r =-0.03, P>0.05) (Figure 1 ).
Single-scan patient study There was no significant relationship (r = 0.3, P> 0.05) between metastasis volume and hepatic parenchymal volume (Figure 2 ).
There was no significant difference (P = 0.09, two-tailed group t-test) in hepatic parenchymal volume between normal liver controls (n = 13, mean volume 1574 ml, s.d. 321 ml) and hepatic metastasis patients (n = 43, mean volume 1308 ml, s.d. 473 ml). (Table I) . Figure 4 shows the correlation of change in metastasis size between that measured using tumour volume and that using WHO criteria. There was good agreement between the two methods in assigning patients to either growth (>25% increase), stable disease (<25% growth to <50% shrinkage) or response () 50% shrinkage) categories.
Discussion
We found no evidence of an inverse relationship between size of hepatic parenchyma and metastases in either the animal study, which measured weight, or the patient single-scan study, which measured volume. We were also unable to demonstrate a significant difference in liver parenchymal volume between subjects with a normal liver and patients with liver metastases.
There was variation in liver parenchymal size in both animal and patient studies. This could not be explained solely by variation in body weight since the liver parenchymal variation (x 2 in rats, x 4 in patients) was greater than body weight variation (x 1.25 in rats, x 2 in patients). been due to errors in accurately assigning tissue to metastasis or normal parenchyma. Previous comparison of human autopsy measurement of liver metastasis volume has suggested a good correlation with CT scan assessment (Heymsfield et al., 1979) . Despite a much larger variation in metastasis size (more than 20-fold) than the potential errors mentioned above, we were unable to show any correlation between metastasis size and liver parenchymal volume.
This suggests that liver parenchyma was not substantially reduced by colorectal liver metastasis growth and indicates a similar effect to that previously reported with growth of 10-fold smaller liver metastases (Purkiss and Williams, 1993) than in our study. Thus, it appears that liver parenchymal volume is preserved throughout the growth of colorectal liver metastases.
It could be that liver parenchymal preservation occurs because metastases grow non-invasively. However, local invasion by liver metastases into the diaphragm suggests that these metastases are readily capable of invasive growth. It is more likely that liver parenchyma is invaded during metastasis growth but that parenchymal regeneration occursperhaps to sustain liver function.
A model of the relationship between PHR and tumour volume during metastasis growth can be derived ( Figure 5 ) which assumes either metastasis replacement of liver parenchyma or parenchymal preservation. It can be seen that the parenchymal preservation model predicts that PHR change underestimates metastasis volume change, particularly at higher (> 400 ml) tumour volumes. A reduction in metastasis volume from 1000 ml to 500 ml (a partial response by volume) would involve a reduction in PHR from 40% to 25% ( Figure 5) We found a good correlation between metastasis volume and WHO criteria in assessment of response.
How should the effect of treatment of colorectal liver metastases be assessed? Tumour volume and not PHR should be assessed where extent of disease is required in studies comparing liver metastasis treatments. WHO criteria provided an equivalent estimate of response, but as they do not yield an estimate of extent of disease, cannot be used to assign patients in order to ensure balanced treatment groups, for example by minimisation (Taves, 1974) .
CT scanning is currently the best widely available method of assessing tumour volume, since it is less operator dependent than ultrasound and allows assessment of size change in more metastases than can usually be measured by ultrasound. However liver ultrasound is more widely available and costs less. Where patients are being treated outside of a trial, operator estimation of metastasis shrinkage using WHO criteria (Miller et al., 1981) or fall in serum carcinoembryonic antigen (CEA) indicates a treatment-derived survival benefit (Allen-Mersh et al., 1987) . Thus, reduction in metastasis size on ultrasound or fall in serum CEA is suitable for assessing routine treatment.
In conclusion, our study suggests that metastasis volume should be reported in liver metastasis treatment studies.
